Ribozyme-mediated RNA assembly and expression

HK40137412APending Publication Date: 2026-09-11UNIVERSITY OF ROCHESTER
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125150
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-10
Filing Date
2026-06-23
Publication Date
2026-09-11

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides compositions, systems and methods for using ribozyme-mediated cis-cleavage and trans-splicing or cis-ligation of RNA molecules to express proteins or fusion proteins of interest.
Need to check novelty before this filing date? Find Prior Art

Description

This invention provides compositions, systems, and methods for expressing target proteins or fusion proteins using ribozyme-mediated cis- and trans-splicing or cis-ligation of RNA molecules. Abstract

Claims

CLAIMS 1. A method of treating a disease or disorder in a subject caused by a mutation in a protein of interest comprising: administering to said subject a first nucleic acid molecule comprising a coding region encoding a first portion of the protein of interest directly linked at the 3’ end to a nucleotide sequence of a ribozyme (3’ribozyme); and administering to said subject a second nucleic acid molecule comprising a coding region encoding a second portion of the protein of interest directly linked on the 5’ end to a nucleotide sequence of a ribozyme (5’ribozyme); wherein self-cleavage of the 3’ribozyme generates a 3’ phosphate at the 3’ end of the first portion of the protein of interest and self-cleavage of the 5’ribozyme generates a 5’ hydroxy group at the 5’ end of the second portion of the protein of interest, allowing for scarless ligation of the protein of interest.

2. The method of claim 1, wherein at least one of the 3’ribozyme and the 5’ribozyme is selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:

219.

3. The method of claim 1, wherein the disease or disorder is one or more selected from the group consisting of: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy (BMD), autosomal recessive polycystic kidney disease, hemophilia A, Stargardt macular degeneration, limb-girdle muscular dystrophies, autosomal recessive profoundprelingual deafness, autosomal recessive nonsyndromic hearing loss (ARNSHL), sensorineural deafness, cystic fibrosis, Wilson Disease, Miyoshi myopathy, autosomal recessive deafness-9 (DFNB9), Usher Syndrome Type I, GJB2-related autosomal recessive non-syndromic hearing loss (GJB2-AR NSHL), Autosomal recessive cerebelloparenchymal disorder type 3, non- syndromic hearing loss, autosomal recessive deafness-16 (DFNB16), Meniere's disease (MD), autosomal dominant non-syndromic sensorineural deafness-12 (DFNA12), autosomal recessive spinocerebellar ataxia-21 (SCAR21), Usher syndrome Type 1F (USH1F), autosomal recessive deafness-23 (DFNB23), autosomal recessive deafness-30 (DFNB30), otospondylomegaepiphyseal dysplasia (OSMED), autosomal recessive deafness-77 (DFNB77), autosomal recessive deafness-84A (DFNB84A), autosomal recessive deafness-84B (DFNB84B), peripheral neuropathy, myopathy, autosomal dominant non-syndromic deafness-4A (DFNA4), congenital thrombocytopenia, sensory hearing loss, autosomal dominant non- syndromic hearing loss-56 (DFNA56), epileptic encephalopathy, Timothy Syndrome, long QT syndrome, X-linked retinal disorder, hyperaldosteronism, autosomal recessive deafness-42 (DFNB42), primary aldosteronism (Conn's syndrome), seizures, neurologic abnormalities, sinoatrial node dysfunction, neurodevelopmental disorders, hypokalemic periodic paralysis, epilepsy, developmental and epileptic encephalopathies, Brody myopathy, Darier's disease, heart disease, von Willebrand disease, and Zellweger syndrome.

4. The method of claim 1, wherein the protein of interest is selected from the group consisting of DMD, PKHD1, F8, ABCA4, DYSF, OTOF, CFTR, ATP7B, MYOF, MYO7A, MYO15A, CDH23, STRC, OTOG, TECTA, PCDH15, TRIOBP, MYO3A, COL11A2, LOXHD1, PTPRQ, OTOGL, MYH14, MYH9, TNC, CACNA1A, CACNA1C, CACNA1F, CACNA1H, CACNA1G, CACNA1D, CACNA1B, CACNA1S, CACNA1I, CACNA1E, ATP2A1, ATP2A2, VWF, PEX1, and CMYA5.

5. The method of claim 1, wherein the first nucleic acid molecule comprises a nucleic acid sequence encoding an N-terminal fragment of a Dystrophin, mini-Dystrophin or micro-Dystrophin protein; and wherein the second nucleic acid molecule comprise a nucleic acid sequence encoding a C-terminal fragment of a Dystrophin, mini-Dystrophin or micro-Dystrophinprotein; and wherein administration of the first and second nucleic acid molecules results in the production of full-length Dystrophin, mini-Dystrophin or micro-Dystrophin protein.

6. The method of claim 5, wherein the first and second nucleic acid molecule are selected from the group consisting of: a) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 150 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 151; and b) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 152 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO:

153.

7. The method of claim 1, wherein the first nucleic acid molecule comprises a nucleic acid sequence encoding an N-terminal fragment of Dysferlin; and wherein the second nucleic acid molecule comprise a nucleic acid sequence encoding a C-terminal fragment of Dysferlin; and wherein administration of the first and second nucleic acid molecules results in the production of full-length Dysferlin protein.

8. The method of claim 7, wherein the first and second nucleic acid molecule are selected from the group consisting of: a) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 157 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 158; b) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 177 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 178; c) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 179 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 178; d) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 181 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 182; and e) a first nucleic acid comprising the nucleic acid sequence of SEQ ID NO: 183 and a second nucleic acid comprising the nucleic acid sequence of SEQ ID NO:

182.

9. The method of claim 1, wherein the first nucleic acid molecule comprises a nucleic acid sequence encoding an N-terminal fragment of STRC; and wherein the secondnucleic acid molecule comprise a nucleic acid sequence encoding a C-terminal fragment of STRC; and wherein administration of the first and second nucleic acid molecules results in the production of full-length STRC protein.

10. The method of claim 9, wherein the first nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO: 160 and a second nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:

161.

11. A system for generating an RNA molecule encoding a protein of interest comprising: a first RNA molecule comprising a coding region encoding a first portion of the protein of interest directly linked at the 3’ end to a nucleotide sequence of a ribozyme (3’ribozyme); and a second RNA molecule comprising a coding region encoding a second portion of the protein of interest directly linked on the 5’ end to a nucleotide sequence of a ribozyme (5’ribozyme); wherein self-cleavage of the 3’ribozyme generates a 3’ phosphate at the 3’ end of the first portion of the protein of interest and self-cleavage of the 5’ribozyme generates a 5’ hydroxy group at the 5’ end of the second portion of the protein of interest, allowing for scarless ligation of the first and second RNA molecules to generate an RNA molecule encoding the protein of interest.

12. The system of claim 11, wherein at least one of the 3’ribozyme and the 5’ribozyme is selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:203, SEQ IDNO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:

219.

13. The system of claim 11, wherein the full length of the protein of interest is greater than 1000 amino acid residues.

14. The system of claim 12, wherein the protein of interest is selected from the group consisting of DMD, PKHD1, F8, ABCA4, DYSF, OTOF, CFTR, ATP7B, MYOF, MYO7A, MYO15A, CDH23, STRC, OTOG, TECTA, PCDH15, TRIOBP, MYO3A, COL11A2, LOXHD1, PTPRQ, OTOGL, MYH14, MYH9, TNC, CACNA1A, CACNA1C, CACNA1F, CACNA1H, CACNA1G, CACNA1D, CACNA1B, CACNA1S, CACNA1I, CACNA1E, ATP2A1, ATP2A2, VWF, PEX1, and CMYA5.

15. A method for generating an RNA molecule encoding a protein of interest comprising: administering to a cell or tissue a first RNA molecule comprising a coding region encoding a first portion of the protein of interest directly linked at the 3’ end to a nucleotide sequence of a ribozyme (3’ribozyme); and administering to a cell or tissue a second RNA molecule comprising a coding region encoding a second portion of the protein of interest directly linked on the 5’ end to a nucleotide sequence of a ribozyme (5’ribozyme); wherein self-cleavage of the 3’ribozyme generates a 3’ phosphate at the 3’ end of the first portion of the protein of interest and self-cleavage of the 5’ribozyme generates a 5’ hydroxy group at the 5’ end of the second portion of the protein of interest, allowing for scarless ligation of the first and second RNA molecules to generate an RNA molecule encoding the protein of interest.

16. The method of claim 15, wherein at least one of the 3’ribozyme and the 5’ribozyme is selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ IDNO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:

219.

17. The method of claim 14, wherein the full length of the protein of interest is greater than 1000 amino acid residues.

18. The method of claim 17, wherein the protein of interest is selected from the group consisting of DMD, PKHD1, F8, ABCA4, DYSF, OTOF, CFTR, ATP7B, MYOF, MYO7A, MYO15A, CDH23, STRC, OTOG, TECTA, PCDH15, TRIOBP, MYO3A, COL11A2, LOXHD1, PTPRQ, OTOGL, MYH14, MYH9, TNC, CACNA1A, CACNA1C, CACNA1F, CACNA1H, CACNA1G, CACNA1D, CACNA1B, CACNA1S, CACNA1I, CACNA1E, ATP2A1, ATP2A2, VWF, PEX1, and CMYA5.

19. An in vitro method of generating an RNA molecule encoding a protein of interest comprising: providing a first RNA molecule comprising a coding region encoding a first portion of the protein of interest directly linked at the 3’ end to a nucleotide sequence of a ribozyme (3’ribozyme); and providing a second RNA molecule comprising a coding region encoding a second portion of the protein of interest directly linked on the 5’ end to a nucleotide sequence of a ribozyme (5’ribozyme); wherein self-cleavage of the 3’ribozyme generates a 3’ phosphate at the 3’ end of the first portion of the protein of interest and self-cleavage of the 5’ribozyme generates a 5’ hydroxy group at the 5’ end of the second portion of the protein of interest, allowing for scarless ligation of the first and second RNA molecules to generate an RNA molecule encoding the protein of interest; andproviding a ligase to induce the assembly of the RNA molecule from the coding region of the first RNA molecule and the coding region of the second RNA molecule.

20. The method of claim 19, wherein at least one of the 3’ribozyme and the 5’ribozyme is selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:

219.

21. A system for generating a circular RNA molecule encoding a protein of interest comprising a nucleic acid molecule encoding: a 5’ ribozyme directly linked to a first portion of a protein of interest, an IRES sequence, and a second portion of a protein of interest directly linked to a 3’ribozyme, wherein self-cleavage of the 3’ribozyme generates a 3’ phosphate at the 3’ end of the second portion of the protein of interest and self-cleavage of the 5’ribozyme generates a 5’ hydroxy group at the 5’ end of the first portion of the protein of interest, allowing for scarless ligation of the 5’ hydroxy group and 3’ phosphate of the RNA molecule to generate a circular RNA molecule encoding the protein of interest.

22. The system of claim 21, wherein the RNA molecule comprises an in vitro transcribed RNA molecule.

23. The system of claim 21, wherein the protein of interest is one or more selected from the group consisting of: a therapeutic protein, a reporter protein, and a Cas9 protein.

24. The system of claim 23, wherein at least one of the 3’ribozyme and the 5’ribozyme is selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ ID NO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:

219.

25. A method of generating a circular RNA molecule in vivo, the method comprising administering to a cell or tissue a linear in vitro transcribed RNA molecule or a DNA molecule encoding a linear RNA molecule, wherein the linear RNA molecule comprises: a 5’ ribozyme directly linked to a first portion of a protein of interest, an IRES sequence, and a second portion of a protein of interest directly linked to a 3’ribozyme, wherein self-cleavage of the 3’ribozyme generates a 3’ phosphate at the 3’ end of the second portion of the protein of interest and self-cleavage of the 5’ribozyme generates a 5’ hydroxy group at the 5’ end of the first portion of the protein of interest, allowing for scarless ligation of the 5’ hydroxy group and 3’ phosphate of the RNA molecule to generate a circular RNA molecule encoding the protein of interest.

26. The method of claim 25, wherein the protein of interest is one or more selected from the group consisting of: a therapeutic protein, a reporter protein, and a Cas9 protein.

27. The method of claim 25, wherein at least one of the 3’ribozyme and the 5’ribozyme is selected from the group consisting of SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135, SEQ ID NO:136, SEQ ID NO:137, SEQ IDNO:138, SEQ ID NO:139, SEQ ID NO:140, SEQ ID NO:141, SEQ ID NO:142, SEQ ID NO:143, SEQ ID NO:144, SEQ ID NO:145, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, SEQ ID NO:174, SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:217, SEQ ID NO:218 or SEQ ID NO:219.